Neukio Biotherapeutics

Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies, announced the completion of a USD 50 million Series A-1 financing round. The funding, led by CD Capital, will support pre-clinical validation, clinical trials, and talent recruitment for its universal off-the-shelf CAR-NK pipeline. Financing DetailsThe…